Reverse Transcriptase Inhibitors: all 1,328 studies that test it

Page 2 of 14. Open to participants first (42), then studies with results posted, then the rest; newest registration first within each.

• More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and AdolescentsCompletedNCT03497676Phase 1/2Results posted
• Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)CompletedNCT03446573Phase 3Results posted
• Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 YearsCompletedNCT03405935Phase 3Results posted
• DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP AdherenceCompletedNCT03387462Phase 4Results posted
• Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and PostpartumCompletedNCT03386578Phase 2Results posted
• Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir AlafenamideCompletedNCT03350672Phase 4Results posted
• Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAMCompletedNCT03311945Phase 3Results posted
• Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsActive, not recruitingNCT03299049Phase 3Results posted
• Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)CompletedNCT03272347Phase 2Results posted
• A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis BCompletedNCT03258710Phase 4Results posted
• ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-AdherenceCompletedNCT03218592Phase 4Results posted
• Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV InfectionCompletedNCT03205566Phase 4Results posted
• A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal CancerCompletedNCT03144804Phase 2Results posted
• Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically SuppressedCompletedNCT03110380Phase 3Results posted
• Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and LamivudineCompletedNCT03078556Phase 1Results posted
• IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration ProjectCompletedNCT03058835Phase 4Results posted
• Body Compartment PK for New HIV Pre-exposure Prophylaxis ModalitiesCompletedNCT02985996Phase 1Results posted
• The Cellular Pharmacology of F-TAF in Dried Blood SpotsCompletedNCT02962739Phase 1Results posted
• Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsActive, not recruitingNCT02951052Phase 3Results posted
• Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsActive, not recruitingNCT02938520Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 InfectionTerminatedNCT02842086Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)CompletedNCT02831764Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)CompletedNCT02831673Phase 3Results posted
• Bone Health in Aging HIV Infected WomenCompletedNCT02815566Phase 4Results posted
• Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) InfectionTerminatedNCT02738008Phase 2Results posted
• Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-LymphomaCompletedNCT02737046Phase 2Results posted
• Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV TreatmentCompletedNCT02707601Phase 3Results posted
• Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With OsteopeniaCompletedNCT02652793Not applicableResults posted
• Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected WomenCompletedNCT02652624Phase 3Results posted
• A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy VolunteersCompletedNCT02634073Phase 4Results posted
• Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 YearsCompletedNCT02616783Phase 3Results posted
• Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184ICompletedNCT02616029Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT02607956Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT02607930Phase 3Results posted
• Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected AdultsCompletedNCT02605954Phase 3Results posted
• Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically SuppressedCompletedNCT02603120Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected AdultsCompletedNCT02603107Phase 3Results posted
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic HemodialysisCompletedNCT02600819Phase 3Results posted
• Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for WomenCompletedNCT02584140Phase 4Results posted
• Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 PatientsCompletedNCT02582684Phase 2Results posted
• Emtricitabine/Tenofovir Alafenamide as Salvage ARTTerminatedNCT02556333Phase 2Results posted
• Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIVCompletedNCT02495779Not applicableResults posted
• Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus InfectionTerminatedNCT02479880Phase 4Results posted
• Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TCCompletedNCT02469246Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected SubjectsCompletedNCT02431247Phase 3Results posted
• Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)CompletedNCT02403674Phase 3Results posted
• PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIVCompletedNCT02401230Phase 4Results posted
• Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT02397694Phase 2Results posted
• Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)CompletedNCT02397096Phase 3Results posted
• Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV InfectionCompletedNCT02384395Not applicableResults posted
• Characterization and Modulation of Mucosal Immunity for HIV Prevention in WomenTerminatedNCT02333045Not applicableResults posted
• Safety & Efficacy of Dual Therapy With Raltegravir/LamivudineCompletedNCT02284035Phase 3Results posted
• Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected AdolescentsCompletedNCT02276612Phase 2/3Results posted
• A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant PhaseCompletedNCT02263079Phase 3Results posted
• Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected AdultsCompletedNCT02246998Phase 4Results posted
• Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated CirrhosisCompletedNCT02224456Phase 4Results posted
• A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)CompletedNCT02217904Phase 1Results posted
• Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in AdolescentsCompletedNCT02213328Phase 2Results posted
• Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRALCompletedNCT02212379Phase 2Results posted
• Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS StudyCompletedNCT02195518Phase 4Results posted
• Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure ProphylaxisCompletedNCT02165202Phase 2Results posted
• Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDFCompletedNCT02121795Phase 3Results posted
• Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)TerminatedNCT02116660Phase 2Results posted
• Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected AdultsCompletedNCT02071082Phase 3Results posted
• Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study (Sibanye Health Project)CompletedNCT02043015Not applicableResults posted
• Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood SpotsCompletedNCT02022657Phase 1/2Results posted
• Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 PatientsCompletedNCT01989910Phase 4Results posted
• Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With EfavirenzTerminatedNCT01980342Phase 4Results posted
• Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive AdultsCompletedNCT01968551Phase 3Results posted
• Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced AdultsCompletedNCT01967940Phase 3Results posted
• Chemotherapy for Relapsed Epstein Barr Virus Associated LymphomaTerminatedNCT01964755Phase 2Results posted
• A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)CompletedNCT01910402Phase 3Results posted
• Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ARTCompletedNCT01903031Phase 2Results posted
• Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.CompletedNCT01878890Phase 1Results posted
• Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal ImpairmentCompletedNCT01818596Phase 3Results posted
• IMPAACT P1092: Steady State PK in Malnourished HIV Infected ChildrenCompletedNCT01818258Phase 4Results posted
• Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsCompletedNCT01815736Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedNCT01797445Phase 3Results posted
• A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention ServicesCompletedNCT01781806Phase 4Results posted
• Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedNCT01780506Phase 3Results posted
• Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / EmtricitabineCompletedNCT01778413Phase 4Results posted
• FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral ReservoirCompletedNCT01777997Phase 4Results posted
• An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)CompletedNCT01769456Phase 2Results posted
• Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in ThailandCompletedNCT01745822Phase 3Results posted
• A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line TreatmentCompletedNCT01709084Phase 3Results posted
• Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive WomenCompletedNCT01705574Phase 3Results posted
• Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or EfavirenzCompletedNCT01695954Phase 1Results posted
• Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning ServicesCompletedNCT01691768Phase 2/3Results posted
• Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B InfectionActive, not recruitingNCT01651403Phase 3Results posted
• Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus RilpivirineCompletedNCT01641809Phase 2Results posted
• A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral FailureCompletedNCT01641367Phase 4Results posted
• Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) ClinicsCompletedNCT01632995Not applicableResults posted
• Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TCTerminatedNCT01620944Phase 3Results posted
• Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child TransmissionCompletedNCT01618305Phase 4Results posted
• Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIVTerminatedNCT01602822Phase 4Results posted
• Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative StressCompletedNCT01585038Phase 4Results posted
• The Rilpivirine Cerebrospinal-fluid (CSF) StudyCompletedNCT01562886Phase 1Results posted
• Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively TreatedCompletedNCT01529749Phase 4Results posted
• Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsCompletedNCT01525628Phase 1Results posted
• Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk WomenCompletedNCT01505114Phase 2Results posted

← Reverse Transcriptase Inhibitors overview